Researchers find new hope for treatment of chronic leukemia
August 16, 2011 by admin · Leave a Comment
New drug, in early clinical testing, offers some clues
Wednesday, August 17, 2011, Cleveland: While testing a new drug designed to treat chronic leukemia, researchers at Cleveland Clinic discovered new markers that could identify which patients would receive maximum benefit from the treatment.
Unconventional hunt for new cancer targets leads to a powerful drug candidate for leukemia
August 2, 2011 by admin · Leave a Comment
The new therapeutic agent, which works against diverse leukemia subtypes, is expected to enter phase I clinical trial within 2 years
Cold Spring Harbor, N.Y. Scientists at Cold Spring Harbor Laboratory (CSHL) and five other institutions have used an unconventional approach to cancer drug discovery to identify a new potential treatment for acute myeloid leukemia (AML). As reported in Nature online on August 3, the scientists have pinpointed a protein called Brd4 as a novel drug target for AML, an aggressive blood cancer that is currently incurable in 70% of patients. Using a drug compound that inhibits the activity of Brd4, the scientists were able to suppress the disease in experimental models.
Weill Cornell drug stops aggressive form of childhood leukemia
May 23, 2011 by admin · Leave a Comment
Combined with the drug Gleevec, the combination therapy eradicates the cancer in cell and animal studies
NEW YORK (May 23, 2011) — In a significant breakthrough, investigators at Weill Cornell Medical College and the University of California, San Francisco, have been able to overcome resistance of a form of leukemia to targeted therapy, demonstrating complete eradication of the cancer in cell and animal studies.
Antibody-guided drug works against acute lymphoblastic leukemia
May 22, 2011 by admin · Leave a Comment
Phase II study shows 61 percent response rate for patients with resistant or recurrent disease
HOUSTON An antibody packaged with a potent chemotherapy drug to selectively destroy acute lymphoblastic leukemia (ALL) cells eradicated or greatly reduced the disease for 61 percent of 46 patients in a phase II study. It will be presented at the 47th annual meeting of the American Society of Clinical Oncology in Chicago June 3-7.
UCSF team discovers key to fighting drug-resistant leukemia
May 17, 2011 by admin · Leave a Comment
Doctors who treat children with the most common form of childhood cancer acute lymphoblastic leukemia are often baffled at how sometimes the cancer cells survive their best efforts and the most powerful modern cancer drugs.
New drug shows potential for treatment-resistant leukemia
April 10, 2011 by admin · Leave a Comment
BOSTON (April 11) –A study from Tufts Medical Center researchers published today finds that a novel drug shows promise for treating leukemia patients who have few other options because their disease has developed resistance to standard treatment.
Tracking down the origin of leukemia relapse
April 3, 2011 by admin · Leave a Comment
The cancer cells that reign during relapses of an aggressive human leukemia are different from those that dominated the original disease, according to a paper published online on April 4 in the Journal of Experimental Medicine (www.jem.org).
New approach to leukemia chemotherapy — is a cure in sight?
March 29, 2011 by admin · Leave a Comment
Speaking at the UK National Stem Cell Network conference in York later today (31 March), Professor Tessa Holyoake from the University of Glasgow will discuss a brand new approach to treating chronic myeloid leukaemia (CML) in which a small number of cancer cells persist despite effective therapy thus preventing cure.
Rituximab and fludarabine produce long-term remissions in CLL
February 23, 2011 by admin · Leave a Comment
COLUMBUS, Ohio New research shows that a less-toxic combination of a targeted immune-based drug and a chemotherapy drug can produce long-term remissions in some chronic lymphocytic leukemia patients. And it does so without increasing the risk of later therapy-related myelodysplastic syndrome and acute myeloid leukemia, which can often occur with a three-drug combination used to treat these patients.
Scientists bioengineer a protein to fight leukemia
February 17, 2011 by admin · Leave a Comment
First report of a recombinant human biotherapeutic active against leukemic stem cells
LOS ANGELES (February 18, 2011) Scientists at the Children’s Center for Cancer and Blood Diseases and The Saban Research Institute of Children’s Hospital Los Angeles today announced a breakthrough discovery in understanding how the body fights leukemia. They have identified a protein called CD19-ligand (CD19-L) located on the surface of certain white blood cells that facilitates the recognition and destruction of leukemia cells by the immune system. This work represents the first report of a bioengineered version of CD19-L, a recombinant human biotherapeutic agent, targeting CD19-positive leukemic stem cells.
